Safety and feasibility assessment
toxicity, toxicities, bone pain, headaches, vomiting, chills
SEVERE ACUTE RESPIRATORY SYNDROME
None of the 10 patients experienced dose-limiting toxicity (DLT) during PB-NK cell infusion or during the 28 days of the post-infusion observation period. One of these patients (P01) died 8 weeks after PB-NK cell infusion because of severe acute respiratory syndrome with a positive test for SARS-COV2 seven days after 2nd infusion. No grade 2–5 toxicities related (possible or probable) to PB-NK cell infusion occurred. Four patients developed grade 1 transient chills, headaches, vomiting and bone pain following each PB-NK cell infusion that were not required hospitalization (Table 
NCI Common Terminology Criteria for Adverse EventsNumber and grade of AEs that were considered to be either probable or possibly related to treatment with infusion of allogenic PB-NK cells. AEs related to conditioning, including fludarabine and cyclophosphamide, are not reported in this tableThe feasibility-related criteria were evaluated in three steps: before the project running and patient selection, during the execution of the trial, and after sampling termination. The number of patients referred to Shariati, Imam Reza, and Yasuj hospitals who were in elapsed/remission status was one case per month, which was the suitable interval for cell production and other patients’ follow-up. Data access in all patients were well access except in P01, where died. (Supplementary file2). NK cell production feasibility was proved by NK cell co-culture results and NK cell immunophenotyping.